1. The WHO Full Value of Vaccine Assessment Concept (0-14 minutes)
2. Rationale for valuing vaccines broadly (14-39 minutes)
3. Full value of vaccination: economic and distributional impacts of novel tuberculosis vaccines in low- and middle-income countries (39 minutes onward)
Dr Philipp Lambach, MD, MBA, PhD works at the World Health Organization’s Department of Immunization, Vaccines and Biologicals. He serves as Secretary of the organization’s Immunization and vaccines related implementation research advisory committee (IVIR-AC) and as acting lead of the Value of Vaccines, Economics, and Modeling (VoV) team. In this capacity he coordinates the review of quantitative methods in vaccine-related research as well as implementation research related to estimating the performance, impact and value of vaccines. In addition to these activities, Dr Lambach leads WHO research efforts on the public health and economic “full” value of specific vaccines (e.g., Influenza and Group B Streptococcus vaccine).
lambachp@who.int
JP Sevilla is a health economist doing research on theoretical and empirical aspects of the full public health and socio-economic value of vaccination. He leads a vaccine evaluation group at Data for Decisions, LLC and is a Research Associate at the Harvard T.H. Chan School of Public Health. He has a Ph.D. in Economics from Harvard University.
jsevilla@hsph.harvard.edu
Dr. Allison Portnoy is an assistant professor in the Department of Global Health at the Boston University School of Public Health. Her research interests include economic evaluation and public health policy, simulation modeling, health equity, and the impact of vaccination on population health and economic outcomes. Dr. Portnoy received a Doctor of Science in the Department of Global Health and Population and completed a postdoctoral fellowship at the Center for Health Decision Science, both at the Harvard T.H. Chan School of Public Health.
aportnoy@bu.edu